Follicular lymphoma (FL) is the most common indolent lymphoma and is characterized by a
relapsing and remitting course. In addition to significant biologic heterogeneity, the clinical …

Simple Summary In this paper, we give an overview on the classification of Follicular
lymphoma as modified in the 5th edition of the WHO classification of haematolymphoid …

Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) treatments have been
rapidly evolving for patients treated in later lines of therapy (LoT). Country-specific cancer …

In the pivotal ZUMA-5 trial, axicabtagene ciloleucel (axi-cel; an autologous anti-CD19
chimeric antigen receptor T-cell therapy) demonstrated high rates of durable response in …

Background Novel therapies for relapsed or refractory follicular lymphoma are commonly
evaluated in single-arm studies without formal comparison with other treatments or historical …

Histologically, melanoma tissues had fewer positive cells percentage of pyroptosis-related
genes (PRGs), GZMA, GSDMB, NLRP1, IL18, and CHMP4A in epidermal than in normal …

Purpose: To investigate the efficacy and safety of the novel orally active PI3Kδ inhibitor in
relapsed and/or refractory patients with follicular lymphoma (FL) who had received at least …

Abstract Knowledge on the pathogenesis of FL is mainly based on data derived from
advanced/systemic stages of FL (sFL) and only small cohorts of localized FL (lFL) have been …

The management of patients with relapsed or refractory follicular lymphoma has evolved
markedly in the last decade, with the availability of new classes of agents (phosphoinositide …

Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor
(CAR) T-cell therapy approved for relapsed/refractory (R/R) follicular lymphoma (FL) …